New council, same biotech hustle
VALANX Biotech is building out its Scientific Advisory Board, which is biotech-speak for: “we’d like some heavyweight brains in the room before we take this thing into the clinic.” John Lambert will chair the board, and Morris Rosenberg plus Peter de Waele are joining him.
Why this matters
The company says the SAB will help bridge the gap between research and clinical application, especially for its antibody-drug conjugate work. In plain English, VALANX wants experienced operators helping it avoid the classic biotech face-plant: promising science that never quite graduates from slide deck to drug candidate.
The ADC angle
The star of the show is VLX-ADC-001, a LIV-1 targeting ADC aimed at metastatic triple-negative breast cancer. VALANX says lead candidate selection is expected in June 2026, so this isn’t just a vanity board announcement — it’s part of the runway toward a meaningful next step.
Investor takeaway
This won’t move the stock like a trial win or FDA green light, but it does add credibility and momentum around the pipeline. In biotech, sometimes the market cares as much about who’s steering the ship as what’s in the cargo hold. Big picture: more expert eyes on the program usually means the company thinks it’s nearing a decision point worth getting right.